Inflammation in children with chronic kidney disease linked to gut dysbiosis and metabolite imbalance

Johannes Holle^{1,2,3*}, Hendrik Bartolomaeus^{2,3,4,5}, Ulrike Löber^{2,3,4,6}, Felix Behrens^{1,3,6,7}, Theda U. P. Bartolomaeus^{2,3,4,6}, Harithaa Anandakumar^{2,4,5}, Moritz I. Wimmer^{2,3,4,5,8}, Dai Long Vu^{4,9}, Mathias Kuhring^{4,6,10}, Andras Maifeld², Sabrina Geisberger^{4,11}, Stefan Kempa^{4,11}, Philip Bufler¹, Uwe Querfeld¹, Stefanie Kitschke¹, Denise Engler¹, Leonard D. Kuhrt^{1,4}, Oliver Drechsel ¹², Kai-Uwe Eckardt⁵, Sofia K. Forslund^{2,3,4,6,13}, Andrea Thürmer¹⁴, Victoria McParland^{2,4}, Jennifer A. Kirwan^{4,9}, Nicola Wilck^{2,3,5,6 #*}, Dominik Müller^{1 #*}

- Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany
- 2 Experimental and Clinical Research Center (ECRC), a cooperation of Charité Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine (MDC), 13125
 Berlin, Germany
- 6 3 DZHK (German Centre for Cardiovascular Research), partner site Berlin, 13316 Berlin,7 Germany.
- 4 Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125
 Berlin, Germany
- 5 Department of Nephrology and Medical Intensive Care Medicine, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany
- 12 6 Charité Universitätsmedizin Berlin and Berlin Institute of Health, 10117 Berlin, Germany
- 13 7 Institute of Physiology, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany
- 8 Department of Internal Medicine IV, Division of Endocrinology, Diabetology and
 Nephrology, University Hospital of Tübingen, 72076 Tübingen, Germany
- 9 Berlin Institute of Health Metabolomics Platform, Berlin Institute of Health (BIH), 10178Berlin, Germany
- 18 10 Core Unit Bioinformatics, Berlin Institute of Health (BIH), 10178 Berlin, Germany
- 19 11 The Berlin Institute for Medical Systems Biology, 10115 Berlin, Germany

20 12 MF1 Bioinformatics, Robert Koch Institute, 13353 Berlin, Germany

21 13 European Molecular Biology Laboratory, 69117 Heidelberg, Germany

14 MF2 Genome Sequencing, Robert Koch Institute, 13353 Berlin, Germany

22

23 # Authors contributed equally to this publication

24 * corresponding authors

25 Abstract

26 Chronic kidney disease (CKD) is characterized by a sustained pro-inflammatory response. 27 The underlying mechanisms are incompletely understood, but may be linked to gut dysbiosis. 28 Dysbiosis has been described in adults with CKD; however, comorbidities limit CKD-specific 29 conclusions. We analyzed the fecal microbiome, metabolites and immune phenotypes in 30 children at three different CKD stages (G3-G4, G5 (hemodialysis), after kidney transplantation) and healthy controls. Serum TNF- α and sCD14 were stage-dependently 31 32 elevated, indicating inflammation and gut barrier dysfunction. We observed microbiome 33 alterations in CKD, including a diminished production of short-chain fatty acids. Bacterial 34 tryptophan metabolites were increased in CKD. CKD serum activated the aryl hydrocarbon 35 receptor and stimulated TNF- α production by monocytes, corresponding to a shift towards 36 intermediate/non-classical monocytes. Unsupervised T cell analysis revealed pro-37 inflammatory shifts in MAIT and Treg cells. Thus, gut barrier dysfunction and microbial 38 metabolites exacerbate inflammation and may therefore contribute to the increased 39 cardiovascular burden in CKD.

40 Introduction

Despite ongoing efforts to improve the treatment of patients with chronic kidney disease (CKD), they still suffer from high morbidity and mortality, primarily due to cardiovascular diseases (CVD)¹. Besides known risk factors such as arterial hypertension and proteinuria¹, recent studies suggest a crucial role for microbially produced metabolites in promoting inflammation^{2,3} and, as a consequence, progression of CKD and CVD^{1,3,4}.

46 There is longstanding evidence showing that an imbalance in the bacterial community 47 residing in the gut with changes in its functional composition, termed dysbiosis, is common in adult patients with CKD^{5,6}. Beyond the influence of CKD, a variety of other factors, such 48 influence of diet and drugs, are suspected to contribute to dysbiosis in CKD⁶. These changes 49 50 are paralleled by an altered bacterial metabolism of nutrients and a systemic accumulation of uremic toxins of bacterial origin, such as indoxyl sulfate (IxS)⁷. It is conceivable that dysbiosis 51 and metabolite dysbalance aggravate systemic inflammation, which could provide a potential 52 53 mechanism for the high rate of premature cardiovascular events³.

Recently, we demonstrated a positive association between IxS and early cardiovascular disease in children with CKD⁸. In contrast to adults with CKD, children are less affected by risk factors such as diabetes, obesity, and metabolic syndrome, but mainly suffer from congenital anomalies of the kidney and urinary tract (CAKUT)⁹. Thus, a pediatric cohort offers the unique opportunity to analyze the impact of CKD on microbiota-host interaction more specifically.

Our cohort includes pediatric CKD patients, those on hemodialysis (HD), patients after kidney transplantation (KT) and age-matched healthy controls (HC). We show, for the first time a CKD specific dataset of gut microbiome composition, altered microbial metabolism of nutrients, and the corresponding impact on inflammation and immune cell dysregulation in children suffering from CKD. We connect the bacterial metabolite dysbalance to a proinflammatory immune cell signature, emphasizing the importance of the microbiota for chronic inflammation in CKD. The fact that these dysbiosis-driven immunological changes

67	are already	detectable in	children w	ith CKD	highlights the	e potential of	microbiota-targeted

68	therapies	to	improve	prognosis	of	CKD	patients	across	all	ages.
----	-----------	----	---------	-----------	----	-----	----------	--------	-----	-------

69 Patients and methods

70 Study population

In this cross-sectional study, we recruited patients from the Department of Pediatric Gastroenterology, Nephrology, and Metabolic Diseases at Charité University hospital in Berlin, Germany, between February 2018 and June 2018. Written informed consent was obtained from all participants and/or their parents prior to study entry. The study was approved by the local Ethical Review Board (EA2/162/17). All procedures performed were in accordance with the ethical standards of the institutional and national research committees and the 1964 Helsinki declaration and its later amendments or comparable standards.

- 78 Patients (age 3-18 years) were enrolled in the following groups:
- CKD group: CKD stage G3-G4, estimated GFR (eGFR) 15-60 ml/min*1.73m²
- HD group: CKD stage G5D, patients on maintenance hemodialysis, enrolled earliest
 four weeks after initiation of HD
- KT group: patients after successful KT, earliest four weeks after KT, without a
 history of rejection or chronic graft failure, eGFR > 60ml/min*1.73m²
- HC group: normal kidney function, treated at the hospital for reasons other than
 kidney disease

We excluded patients with a body weight below 15kg, acute or chronic inflammatory diseases, fever, diabetes, chronic liver disease, inflammatory bowel disease, or other gastrointestinal disorders (constipation, diarrhea, short bowel syndrome). Patients with antibiotic prophylaxis or treatment within the four weeks prior to recruitment were excluded.

90 Statistical analysis

Microbiome and metabolome analysis: Alpha diversities of microbial communities (Shannon
 diversity as computed by RTK, defined at the OTU level) were compared between groups
 using Kruskal-Wallis (KW) test. Beta diversity was assessed using Euclidean (metabolome)

94 and Canberra (microbiome) dissimilarity index between samples computed using vegan 95 package v2.5-7. Principal Coordinates Analysis (PCoA) was performed using the vegan 96 package v2.5-7 (employing Euclidean and Canberra distance metrics as above). 97 PERMANOVA was performed using the adonis function from the vegan package v2.5-7. We 98 estimate differential abundance on phylum and genus level between groups using the 99 package DESeq2 v1.30.1. The DESeq2 pipeline uses negative binomial distribution models 100 to test for differential abundance between testing conditions. We ran the pipeline with 101 normalized counts under default settings. P values were adjusted according to Benjamini-102 Hochberg (BH) false discovery rates (FDR) correction. A q-value of <0.1 was considered 103 statistical significant.

104 For each pair of patient groups, features from the TRP analysis were compared using two-105 sided Mann-Whitney-U (MWU) tests with effect sizes calculated as Cliff's delta metric per the 106 R ordom package v3.1. Effect sizes were taken as Spearman's rho. All significance 107 estimates were adjusted for multiple tests using BH-FDR correction. To assess the effect of 108 patient groups on tryptophan pathway metabolites (concentrations), multifactor ANOVAs 109 were calculated per metabolite to account for multiple groups as well as potential 110 confounders (including age, sex, ethnical background, underlying disease category, BMI, and 111 eGFR).

The co-abundance network of host, microbiome and metabolome features was calculated from the dataset as a whole by assessing pairwise Spearman correlations and adjusted for multiple testing using BH-FDR correction as implemented in the R psych package v1.9.12. Edges for which absolute rho > 0.3 and Q < 0.1 were visualized using the iGraph R package. Correlations were separately also assessed stratifying for group effects using the R coin package v1.3.1.

Flow cytometry: For all FlowSOM clusters we computed log2 fold changes (fc). Cluster log2fc
 were visualized using ggplot2 package v3.3.5. For all subpopulations of Treg and MAIT cells,
 we calculated log2fc and assessed statistical significance using two-sided MWU-tests

121 between HD and HC with BH-FDR correction. A q-value of <0.1 was considered statistically

significant. Data was visualized using the EnhancedVolcano package v4.1.2.

Boxplots: Analysis and graphical representation was performed in GraphPad Prism 9.3.1 (GraphPad Software, CA, USA). Boxplots depict median and interquartile range with whiskers from min to max. Overlaid data points represent individual patients or measurements. Normality was assessed using Q-Q-plots and Shapiro-Wilk test. For more than two groups we performed one-way ANOVA with Tukey post-hoc test or KW test with Dunn's post-hoc test, as appropriate. For two group comparisons, we performed two-sided Student's t-test or two-sided MWU test, as appropriate.

130 For all analysis *P* value of <0.05 (unadjusted or adjusted, as appropriate) and a *Q* value of

131 <0.1 was considered statistically significant.

132 **Results**

133 Childhood CKD marked by arterial hypertension, inflammation and leaky gut

134 Ten healthy individuals (HC) and 38 patients were enrolled in the study (Supplementary 135 Figure 1). Baseline characteristics are given in Table 1. Participant mean age was 10.6 ± 3.8 136 years with 21 females and 27 males. CAKUT was the most prevalent underlying disease 137 category. Patients treated with HD had a median time on dialysis of six months (range 3 - 29138 months) with a median residual diversis of 50 ml per day (range 0 - 1800 ml per day) and a mean Kt/Vof 1.56 ± 0.27 (SD), indicating adequacy of HD treatment. Patients after KT had a 139 140 stable graft function with a mean eGFR of 78.8 ± 19.4 ml/min*1.73m². The median time from 141 transplantation was 48 months (range 10 – 125 months).

142 Both the CKD group (CKD stage G3-G4) and the HD group (CKD stage G5D) were 143 hypertensive (83% and 91%, respectively) and received antihypertensive treatment (1.8 \pm 144 1.5 antihypertensive drugs in the CKD group and 2.4 ± 1.9 drugs in the HD group, Figure 1a, 145 Table 1). Six HD patients (55%) exhibited hypertensive blood pressures at the time of study 146 enrolment despite treatment (Table 1). In the HD and CKD groups serum levels of the pro-147 inflammatory cytokine TNF- α were stage-dependently increased and significantly higher than 148 in the HC group (Figure 1b), while differences in the levels of other pro- and anti-149 inflammatory cytokines did not reach significance (Supplementary Table 2). Notably, TNF- α 150 was also significantly elevated in patients after KT compared to HC (Figure 1b). We next investigated serum levels of the tight junction protein zonulin-1 (Zo-1) and the 151 152 lipopolysaccharide (LPS) binding protein soluble CD14 (sCD14), which were elevated in 153 CKD and HD compared to control and KT (Figure 1c), indicating stage-dependent intestinal 154 barrier dysfunction and CKD-associated endotoxemia. Thus, in the absence of classical 155 cardiovascular risk factors other than hypertension, CKD in children is characterized by 156 elevated serum markers of inflammation and leaky gut.

157 Microbiome alterations in CKD

158 Since intestinal barrier dysfunction may be associated with dysbiosis, we next sought to 159 analyze the taxonomic composition of the gut microbiome. We performed 16S amplicon 160 sequencing in n=32 study participants with available fecal samples. We observed a high 161 interindividual compositional variability at phylum level (Figure 2a). Microbiome richness and 162 diversity, as measured by the Shannon diversity index, tended to be lower in CKD and HD 163 patients compared to HC but this difference did not reach statistical significance (Figure 2b). 164 However, analysis of beta diversity (Canberra distance) indicated significant differences in 165 microbiome composition between groups, with CKD and HD groups separating most clearly 166 from the HC (Figure 2c, p = 0.01). Analysis of bacterial composition on genus level revealed 167 significant alterations predominantly in HD patients (Figure 2d). First, relative abundances of 168 Firmicutes and Actinobacteria such as Fusicatenibacter (belonging to the family of 169 Lachnospiraceae), Subdoligranulum (Ruminococcaceae), and Bifidobacterium 170 (Bifidobacteriaceae) were significantly diminished in HD patients compared to HC. Second, 171 we found an increase in relative abundance of Proteobacteria and Bacteroidetes, such as 172 Citrobacter (Enterobacteriaceae), Parasutterella (Parasutterellaceae), and several genera of 173 Bacteroides (Bacteroidaceae) in CKD and HD groups compared to HC and KT. Taken 174 together, the taxonomic microbiome changes in CKD are stage-dependent, most pronounced 175 in the HD group and less pronounced after KT. The abundance of proteolytic bacteria (such 176 as Citrobacter) increases in CKD whereas saccharolytic bacteria (such as Bifidobacterium) 177 decrease.

178 CKD stage-dependent dysbalance of bacterial metabolites

To investigate the functional effects of the observed alterations in microbiome composition on host physiology, we focused a plasma metabolite analysis on tryptophan (TRP) metabolites and SCFA. Dietary TRP is a substrate for both cellular metabolism and bacterial proteolytic fermentation and the latter is a source of microbial produced uremic toxins, such as IxS. We found significant differences in the abundance of TRP metabolites in CKD and HD compared to the HC and KT groups (Figure 3a). CKD and HD patients showed a large-

185 scale shift from TRP to its indole and kynurenine (KYN) metabolites, which was 186 predominantly driven by an increase of IxS (Figure 3b). We found a significant decrease in 187 plasma TRP concentrations in patients with CKD and HD, while IxS and 5 KYN metabolites 188 (KYN, kynurenic acid (KA), 3-OH-kynurenine (3OH-KYN), anthranilic acid (AA), xanthurenic 189 acid (XA)) were significantly elevated (Figure 3c). Interestingly, patients after KT had similar 190 metabolite levels compared to HC with the exception of KYN and 3OH-KYN (Figure 3c). 191 Individual values of TRP, IxS and, KA are shown across the different groups in Figure 3d-f. 192 The activation of the cellular KYN pathway is also indicated by the ratio of KYN to TRP, 193 which was significantly elevated in CKD and HD (Figure 3g). A multivariate ANOVA showed 194 that age, sex, ethnic background, underlying disease category, and BMI did not confound 195 metabolite levels. Only group and eGFR had an impact on several of the compounds 196 (Supplementary Table 3), confirming their accumulation with declining eGFR. Because indole 197 and KYN metabolites have been shown to activate the aryl hydrocarbon receptor (AhR), a 198 transcription factor and potential mediator of microbiome-host interactions, we measured the 199 AhR activating potential of serum from the HD and HC group in vitro using a cell-based 200 reporter assay. Serum from HD patients induced a significantly higher AhR activity as 201 compared to HC (Figure 3h). Similarly, IxS activates the AhR in a dose-dependent manner 202 (Supplementary Figure 2).

203 To further functionally validate our findings of decreased abundancies of saccharolytic 204 microbes, we measured the abundance of a central enzyme for bacterial SCFA production 205 by qPCR of fecal DNA using degenerate primers. The abundancy of the butyrate gene was 206 lower in the DNA extracted from fecal samples of HD patients relative to the other patient 207 groups (Supplementary Figure 3a). Next, we measured SCFA in serum. The SCFA 208 propionate and isobutyrate were reduced in patients with HD compared to HC, while serum 209 concentrations of butyrate did no differ significantly between groups (Supplementary Figure 210 3b). Thus, we were able to show on a functional level that the observed stage-dependent 211 microbiome changes have an impact on the production and abundance of bacterial 212 metabolites.

213 In order to comprehensively visualize the relationship of clinical, microbial and metabolomic 214 parameters, we performed a correlation network analysis (Figure 4). Here, TNF- α correlated 215 positively with sCD14, Proteobacteria, IxS, several KYN metabolites and biomarkers of 216 kidney function (Figure 4a, positive correlations). Conversely, the SCFA propionate and 217 isobutyrate correlated inversely with TNF- α , IxS, KYN metabolites and kidney function 218 (Figure 4b, negative correlations). Firmicutes correlated positively with microbial diversity, 219 butyrate and I3PA. These associations support our assumption of kidney function as a 220 catalyst of gut bacteria-driven inflammation.

221 Monocyte subsets contribute to the pro-inflammatory phenotype in CKD

222 The AhR is expressed in various immune cells including myeloid cells and is known to modulate their function¹⁰. It is assumed that the accumulation of AhR ligands in CKD leads to 223 224 immune cell activation. We therefore isolated monocytes from healthy donors and incubated 225 them with serum from HD patients or HC. Monocytes incubated with HD serum showed a 226 significantly higher TNF- α production (Figure 5a). Similarly, incubation of isolated monocytes 227 with IxS dose-dependently increased TNF-a production which could be reversed by co-228 incubation with the synthetic AhR-antagonist CH-223191, highlighting the importance of 229 AhR-mediated immune activation in CKD (Figure 5a).

230 In order to get a broader overview of changes in relevant immune cell populations in CKD, 231 we re-collected peripheral blood mononuclear cells (PBMC) from seven HC and six HD 232 patients for immunophenotyping using flow cytometry. Unsupervised FlowSOM analysis¹¹ of 233 our monocyte and dendritic cell targeting flow panel (see Supplementary table 1, 234 supplementary figure 4, Figure 5b), showed phenotypic alterations of monocytes (cluster 3, 235 Figure 5c) being decreased (Figure 5d) and dendritic cell (cluster 7, Figure 5c) being 236 increased (Figure 5d) in HD patients. Using classical hierarchical gating, we observed similar 237 abundances of total monocytes (identified by HLA-DR, CD14, and CD16 as described in¹²), 238 but a significant shift from classical (CD14+CD16-) towards non-classical (CD14-CD16+) and intermediate (CD14+CD16+) monocytes in HD (Figure 5e), the latter two being known for 239

their potent production of TNF- α^{13} . Hierarchical gating within the dendritic cell population revealed no significant differences of dendritic cell types (Supplementary Figure 5). Thus, HD patients are characterized by alterations within myeloid cells, showing a shift from classical to pro-inflammatory intermediate and non-classical monocytes.

244 Pro-inflammatory T cell subsets in CKD

245 Since SCFA and TRP metabolites are known to modulate T cell differentiation and function, 246 we expanded our flow cytometry to include analysis of T cells (Supplementary table 1, T 247 surface panel, supplementary figure 4). We again performed FlowSOM analysis using 8 248 clusters (Figure 6a). Mucosal associated invariant T (MAIT) cells and a subpopulation of 249 regulatory T cells (Treg) (Clusters 6 and 3, respectively, Figure 6b) exhibited the largest 250 effects between HD and HC patients (Figure 6c). We confirmed this finding by classical 251 hierarchical gating, with circulating MAIT cells (CD3+CD161+TCRV α 7.2+) being decreased 252 in HD (Supplementary Figure 6a). Next, we performed a more detailed analysis of MAIT cell 253 subpopulations. After adjusting for multiple testing, we found a decrease of CD4-CD8- MAIT 254 cells, while CD4+CD8- and CD4+CD8+ cells were enriched in HD (Figure 6d, f). Moreover, 255 MAIT cells of HD patients displayed an effector memory phenotype (CD45RA-, CD62L-) and 256 expressed more PD-1, indicative of increased activation. Importantly, upon in vitro 257 restimulation, MAIT cells of HD patients secreted significantly more interleukin-17A (IL-17A) 258 (Figure 6d, f).

259 In addition, we identified changes within a CD4+CD25+CD127- cell cluster (Cluster 3, Figure 260 6a-c), indicating alterations in Treg subpopulations. Total Treg proportions were not altered 261 between HC and HD (Supplementary Figure 6b). However, since different subpopulations 262 with partly different functions are known to exist within the total Treg population, we extended 263 the Treg characterization (Supplementary table 1, T surface and T activation)¹⁴. Adjusted for 264 multiple testing, several Treg subpopulations, characterized by activation markers and 265 chemokine receptors, were significantly changed in HD patients (Figure 6e). In detail, Treg 266 from HD patients with a central-memory phenotype (CD45RA-, CD62L+) showed a higher

267	expression of PD-1 indicating activation state. Based on the expression of chemokine
268	receptors, Th1-like (CXCR3+), Th17-like (CXCR3-CCR6+CCR4+CCR10-) and Th22-like
269	(CXCR3-CCR6+CCR4+CCR10+) Treg were significantly diminished in HD patients
270	compared to HC (Figure 6e, g). Taken together, we observed significant alterations in T cell
271	subtypes, namely MAIT cells and Treg, which play an important role in mucosal immunity
272	and inflammation.

273 Discussion

274 Inflammation is a hallmark of CKD, detectable even at young age and particularly prognosis-275 determining. We show in children with CKD, that intestinal barrier dysfunction and dysbiosis 276 are associated with a systemic bacterial metabolite imbalance that contributes to the pro-277 inflammatory phenotype of several immune cells including monocytes and T cells. We also 278 provide novel insight into the microbiota-immune crosstalk mediated by TRP metabolites and 279 SCFA in CKD. Thus, we demonstrate a stage-dependent aberration of the microbiome-280 immune axis, which is both a contributor to inflammation and a potential target for anti-281 inflammatory therapeutic strategies.

282 The young cohort enrolled for this study exhibits a markedly increased risk for cardiovascular 283 disease, indicated by a high prevalence of arterial hypertension despite antihypertensive 284 treatment as well as clear evidence of systemic inflammation (TNF- α). Inflammation is considered to be a main driver of cardiovascular disease in CKD¹⁵. Early cardiovascular 285 pathologies and complications in children with CKD have been described previously^{16,17}, the 286 287 burden of which accumulates with age and causes a fatal increase of CKD-associated 288 mortality¹. This is remarkable given that CKD occurs in children in the virtual absence of 289 diseases that can cause both CKD and CVD, such as diabetes and metabolic syndrome. 290 This is particularly relevant for the present study, as traditional comorbidities in adults 291 represent additional influences on microbiota-immune interaction. Therefore, it can be 292 assumed that the microbiome and immune signatures presented here are influenced to a 293 smaller degree by traditional comorbidities and represent specific signatures of CKD.

For the first time, we demonstrate that children with CKD already exhibit considerable stagedependent intestinal barrier dysfunction indicated by increased serum levels of Zo-1 and sCD14. Zo-1 regulates intestinal permeability¹⁸ and has been associated with impaired barrier function in various conditions such as obesity, diabetes¹⁹ and autoimmune diseases²⁰. Impaired barrier function permits the translocation of luminal LPS into the circulation. Consequently, we detected a CKD stage dependent increase in serum levels of the LPS

binding protein sCD14, suggesting LPS-induced inflammation²¹⁻²³. Elevated serum levels of 300 301 sCD14 have been associated with an increased risk of CVD in two independent cohort 302 studies^{24,25}. Intestinal barrier dysfunction develops along with or as a consequence of 303 dysbiosis, presumably as a consequence of a dysbalance of microbial metabolites, such as SCFA^{26,27}. Therefore, we analyzed the composition of the gut microbiome in our cohort. In 304 305 line with studies of adult CKD patients^{5,7,28,29}, we observed CKD stage-dependent 306 compositional changes. This microbial signature was most dominantly present in patients 307 with HD increase of proteolytic bacteria such displaying an as Citrobacter 308 (Enterobacteriaceae) and a decrease of saccharolytic bacteria such as Bifidobacterium 309 (Bifidobacteriaceae), Fusicatenibacter (Lachnospiraceae) and Subdoligranulum 310 (Ruminococcaceae). Since adults, unlike children, may well exhibit a variety of comorbidities 311 whose presence can have an additional obscuring influence on the microbiome (e.g. diabetes³⁰, obesity³¹, and fatty liver disease³²), it can be assumed that the data presented 312 313 here are less influenced by such comorbidities and therefore appear to be more clearly CKD-314 associated.

315 The enrichment of Enterobacteriaceae found in HD patients affects the microbial metabolism 316 of nutrients as they express tryptophanases that metabolize TRP to indoles²⁹. Dietary TRP is 317 metabolized both by somatic cells and by the intestinal microbiota to metabolites with various functions^{33,34}. We found that TRP metabolites in the blood of CKD patients increased in a 318 319 stage-dependent manner, which was predominantly driven by the disproportional increase of 320 metabolites of bacterial origin. Therefore, dysbiosis and intestinal barrier dysfunction, as 321 present in CKD and HD patients in our cohort, are likely contributing to the accumulation of uremic solutes³⁵ in addition to their reduced renal elimination^{29,36}. 322

In our cohort, microbially-derived IxS and ILA as well as host-derived KYN, 3HK, KA, XA and AA were significantly elevated in CKD and HD patients, while serum levels of TRP were reduced. Both indole and KYN derivates are ligands of the AhR, thereby influencing innate and adaptive immune responses^{10,33,34}. Consequently, the AhR activation potential of serum

from our HD patients was increased, confirming previous findings in adults³⁷. Of note, the degradation of TRP to KYN metabolites is regulated by tryptophan 2,3-dioxygenase in the liver, which is upregulated by chronic inflammation³⁸ and influenced by diabetes³⁹⁻⁴¹ and obesity⁴². In contrast to previous studies³⁹⁻⁴¹, our study emphasizes enhanced TRP metabolism and AhR activation in CKD irrespective of traditional comorbidities.

332 Myeloid cells are known to be modulated by the AhR and are thus particularly affected by uremic TRP metabolites^{10,33,34}. As indicated by unsupervised clustering and confirmed by 333 334 hierarchical gating we demonstrated a pathological shift from classical towards intermediate 335 and non-classical monocytes in HD patients. This monocyte signature has previously been associated with an increased risk of CVD^{43,44}. Most notably, we showed that isolated 336 monocytes exhibited a higher production of TNF-a after incubation with serum from patients 337 338 treated by HD compared to HC, which was dependent on AhR function. Thus, the increased 339 TNF- α concentrations in the circulation are at least partly a consequence of the effect of the 340 increased and mainly microbially produced TRP metabolites on the AhR of monocytes, and 341 possibly also other immune cells.

342 In line with the depletion of SCFA-generating saccharolytic bacteria⁴⁵, such as 343 Bifidobacterium, Fusicatenibacter and Subdoligranulum in CKD and HD patients, we show 344 lower systemic levels of the SCFA propionate. There is a growing body of evidence about the pivotal role of SCFA in local gut homeostasis and the protection from CVD in vitro⁴⁶ and in 345 346 vivo⁴⁷. Since SCFA are known to enhance the abundance and suppressive function of Treg cells in mice⁴⁸ and humans⁴⁹, we analyzed T cells by multi-color flow cytometry. Based on 347 the expression of chemokine receptors^{14,50}, we found a decrease of Th1-like, Th17-like and 348 349 Th22-like Treg in HD patients. The lower frequencies of these Treg subtypes might be explained by both, lower peripheral induction as a consequence of reduced availability of 350 SCFA⁴⁸ and increased recruitment of Treg to sides of inflammation, e.g. atherosclerotic 351 352 plagues⁵¹. Moreover, the frequency of dysfunctional Treg with a central memory phenotype 353 expressing PD-1 was elevated in HD patients. Circulating Treg expressing PD-1 are known

to exhibit reduced suppressive function and molecular signatures of exhaustion⁵². In light of the recognized importance of chronic inflammation for CVD development, the diminished anti-inflammatory function as a consequence of reduced abundances of Treg subtypes and increased abundances of dysfunctional, exhausted Treg is likely to play a role in CVD development^{50,51}.

359 Interestingly, our unsupervised FlowSOM analysis clearly indicated that circulating MAIT 360 cells were reduced in HD patients, expressed markers of exhaustion (PD-1) and produced 361 higher amounts of IL-17A. This pattern has been described for several autoimmune, 362 inflammatory and cardiometabolic diseases⁵³, such as obesity and type two diabetes⁵⁴. It is 363 still a subject of discussion whether decreased MAIT cell abundances are mainly a consequence of migration to inflamed tissue or increased apoptosis⁵³. In animal models, 364 365 MAIT cells can promote inflammation and microbial dysbiosis leading to metabolic dysfunction during obesity⁵³. A large cross-sectional analysis in patients with cardiometabolic 366 367 diseases highlighted the positive association between decreased MAIT cell abundances and cardiovascular disease risk⁵⁵. A reduction of MAIT cell abundance has been described in 368 369 CKD of predominantly diabetic cause, albeit without functional cytokine expression as shown here⁵⁶. Taken together, Treg and MAIT are two important cell populations phenotypically 370 371 altered in HD patients that are known to be regulated by the microbiota, further emphasizing 372 the importance of the microbiota-immune axis in CKD.

373 Noteworthy, patients after KT still showed significantly elevated serum levels of TNF-a 374 compared to HC, albeit lower than in CKD and HD. There were no differences in serum 375 markers of intestinal barrier function and only slight alterations in the microbiota composition, 376 although the limited size of our cohort is less suited to detect fine-scaled differences between 377 HC and KT. While microbial SCFA and indole metabolism apparently recovers after KT, 378 serum levels of KYN and 3HK were still elevated. In contrast, adult patients after KT 379 exhibited a significant decrease in alpha diversity and an increase of Proteobacteria, which is in part driven by the use of immunosuppressive drugs⁵⁷. In a murine kidney transplantation 380

model, mice after allograft transplantation exhibited dysbiosis even in the absence of antibiotics and immunosuppression⁵⁸. As gut dysbiosis and impaired microbial production of SCFA seem to play a role in allograft rejection as well⁵⁸, the absence of dysbiosis in children after KT might attribute to a more favorable transplant outcome in children compared to adults.

386 In conclusion, the present study is the first to show CKD stage-dependent alterations of the 387 microbiota-metabolite-immune axis in children with CKD in the absence of comorbidities 388 seen in adult patients. Our data demonstrate alterations at all levels of this pivotal axis. In 389 this context, TRP metabolites act as a mechanistic link between the microbiota and the 390 immune system, contributing to a pro-inflammatory phenotype in an AhR-dependent manner 391 - even at a young age. SCFA deficiency may further exacerbate CKD-associated chronic 392 inflammation and intestinal barrier dysfunction. These data provide strong evidence that the 393 microbiota is an important stimulus for persistent inflammation. Restoring intestinal eubiosis 394 could favorably influence the pro-inflammatory sequelae. Therefore, the microbiota appears 395 a promising target of future therapeutic strategies aimed at sustained containment of 396 inflammation to prevent chronic sequelae such as CVD and premature mortality in CKD.

397 Acknowledgments

398 This work was supported by local resources of the participating institutions. JH was 399 supported by the Peter-Stiftung für die Nierenwissenschaft. JH, MW, SKF, and UL were 400 supported by the German Center for Cardiovascular Research (DZHK), partner site Berlin. 401 UL was supported by the German Federal Ministry of Education and Research (EMBARK; 402 01KI1909B) under the frame of JPI AMR (EMBARK; JPIAMR2019-109). S.G. was supported 403 by the Bundesministerium für Bildung und Forschung funding MSTARS (Multimodal Clinical 404 Mass Spectrometry to Target Treatment Resistance). F.B. was supported by the Berlin 405 Institute of Health BIH-MD-TRENAL stipend. NW was supported by the European Research 406 Council (ERC) under the European Union's Horizon 2020 research and innovation program 407 (852796) and by a grant from the Corona-Stiftung in the German Stifterverband. NW and 408 SKF were supported by the Deutsche Forschungsgemeinschaft (German Research 409 Foundation, SFB 1365 and SFB 1470). The sponsors had no involvement in study design, 410 data collection, analysis and interpretation of data and in the decision to submit this article for 411 publication.

The authors thank Gudrun Koch, Jana Czychi, Gabriele N'diaye and Kerstin Sommer for their technical assistance and Nadine Unterwalder for her kind support in analyzing serum cytokine levels.

415

416 Author contributions


J.H., N.W. and D.M. led and conceived the project. J.H. and H.B. designed and performed most experiments, analyzed and interpreted the data. J.H., S.K., D.E. and L.D.K. conducted patient recruitment under supervision of D.M.. U.L., T.U.P.B., H.A. and S.K.F. performed the statistical analyses and data integration. J.H., H.B., M.I.W. and A.M. performed and analyzed flow cytometry. V.MP. performed most of the *in vitro* experiments. A.T. and O.D. performed 16S sequencing. D.L.V., M.K., S.G., S.K. and J.A.K. performed metabolite analysis. P.B.,

- 423 K.U.E., N.W., and D.M. helped with data interpretation. N.W. supervised the experiments and
- 424 data analysis. J.H., H.B. and N.W. wrote the manuscript with key editing by F.B., U.Q. and
- 425 K.U.E. and further input from all authors.
- 426
- 427 **Competing interest:** None declared.
- 428


429 Data availability

430 All data produced in the present study are available upon reasonable request to the authors.

431 Figures




432 433 Figure 1: Arterial hypertension and systemic inflammation are linked to impaired 434 intestinal barrier function in pediatric chronic kidney disease. The number of 435 antihypertensive drugs per individual (a, n= 48 patients) is shown in patients with chronic 436 kidney disease (CKD G3-4), hemodialysis (HD), after kidney transplantation (KT) and healthy 437 controls (HC). Plasma TNF- α (b, n=46 patients) was analyzed by chemiluminescence 438 immunoassay. Gut barrier function was assessed using Zonulin 1 and soluble CD14 (c, n=40 439 patients) ELISA measurements in plasma. Data is shown as a box (median and interguartile 440 range) and whiskers (min-max) with overlaid dot plot. P values \leq 0.05 are shown, as 441 measured by ordinary one-way ANOVA or Kruskal-Wallis test followed by Tukey's or Dunn's 442 post-hoc correction for multiple comparisons, as appropriate.



444 445 Figure 2: Characteristics of gut microbiota in a cohort of pediatric patients with 446 chronic kidney disease compared to healthy controls. Analysis of gut microbiota from 447 16S rRNA sequencing in children (n = 32) with chronic kidney disease (CKD G3-4), patients 448 with hemodialysis (HD), patients after kidney transplantation (KT) and healthy controls (HC). 449 a) Relative abundance on phylum level of individuals according to their respective group. b) 450 Alpha diversity as measured by Shannon diversity. Data is shown as a box (median and 451 interguartile range) and whiskers (min-max) with overlaid dot plot. c) Beta diversity 452 assessment by Principal Coordinate Analysis (PCoA) based on Canberra distance (p = 0.01 453 by PERMANOVA). d) Analyses of group differences on genus level are shown as a heatmap. 454 Patient groups were tested against each other (pairwise). The heatmap shows significant

changes in abundance using DESeq2 v1.30.1 package. Multiple groups of the same genus
reported by Lotus due to lacking coverage in available phylogenetic databases are marked
by numbers. Bar charts (right) show abundance and prevalence; abundance is calculated as
log(genus count)/log(max(genus count)); prevalence for each genus is calculated across the
whole data set. All significance estimates were adjusted for multiple tests using BenjaminiHochberg FDR correction.



461

462 Figure 3: Stage-dependent activation of plasma tryptophan metabolism activates the Aryl-hydrocarbon receptor. Tryptophan (TRP) and its metabolites were measured in 463 464 plasma of children at different stages of chronic kidney disease (CKD) compared to healthy 465 controls (n = 48). a) Multivariate analysis (Principal Coordinate Analysis) of all measured 466 metabolites discriminates between patients with CKD G3-4, patients with hemodialysis (HD), 467 patients after kidney transplantation (KT) and healthy controls (HC). b) Cumulative load of 468 TRP and its metabolites. c) Univariate analysis depicted as heatmap shows effect sizes 469 (Cliff's delta) for each pair of patient groups. Colours denote the effect directions (blue-470 positive and red-negative) and magnitudes (the darker the colour, the stronger the 471 magnitude); asterisks represent the association significance. Statistical significance was 472 assessed by Mann-Whitney U-test and Benjamini-Hochberg false discovery rate correction.

473 Group differences of TRP (d), indoxyl sulfate (IxS, e) and kynurenin acid (KA, f) were further 474 visualized in box plots. The Kynurenine/Tryptophan ratio (g) indicates the activity of 475 tryptophan degradation to kynurenine metabolites. The activity of the Aryl-hydrocarbon 476 receptor (AhR, h) was analyzed using a transfected reporter cell line after 48 hrs incubation 477 with serum of HC (n=7) and HD (n=10) patients. P values ≤ 0.05 are shown, as measured by 478 ordinary one-way ANOVA or Kruskal-Wallis test and adjusted by post-hoc Tukey's or Dunn's 479 correction for multiple testing (d-g) or by t test (h). Data is shown as a box (median and 480 interguartile range) and whiskers (min-max) with overlaid dot plot. 481 Abbreviations: TRP= tryptophan, 5OH-TRP= 5-hydroxy-tryptophan, TRYP= tryptamin, KYN=

- 482 kynurenine, 3OH-KYN= 3-hydroxy-kynurenine, KA= kynurenic acid, AA= anthranilic acid,
- 483 XA= xanthurenic acid, IxS= indoxyl sulfate; I3CA= indole-3-carboxyaldehyde, I3PA= indole-
- 484 3-propionic acid, ILA= indole lactate, AhR= aryl hydrocarbon receptor.







Figure 4: Correlation network of gut microbiome, clinical parameters, plasma tryptophan metabolites and cytokines. Laboratory parameters, tryptophan metabolites (n = 48), cytokines (n=46) and taxonomic data (n = 32) were associated using pairwise Spearman correlations and adjusted for multiple testing using the Benjamini-Hochberg FDR correction. Edges for which absolute rho > 0.3 and Q < 0.1 are visualized. For better visualization eGFR was removed as creatinine and urea convey similar information. a) Positive correlations. b) Negative correlations.

Abbreviations: TRYP= tryptamin, TRP= tryptophan, KYN= kynurenine, KA= kynurenic acid,
3OH-KYN= 3-hydroxy-kynurenine, AA= anthranilic acid, XA= xanthurenic acid, PA= propionic
acid, BA= butyric acid, Iso-BA= isobutyric acid, Zo-1= zonulin-1, sCD14= soluble CD14, IxS=
indoxyl sulfate, ILA= indole lactate, I3CA= indole-3-carboxyaldehyde, I3PA= indole-3propionic acid, CrP= C-reactive protein. Crea= creatinine, phos= phosphate, Alb= albumin.





- 510 monocytes (CD16+), non-classical (CD14+), and intermediate (CD14+CD16+) monocytes is
- 511 shown in e).
- 512 Abbreviations: AhR= aryl hydrocarbon receptor.



513

Figure 6: Pro-inflammatory T cell subtypes in chronic kidney disease. Unsupervised clustering of HD (n=6) and HC (n=7) individuals by FlowSOM revealed 8 T cell clusters (a) based on the differential expression of surface marker (b). c) Cuneiform plots showing the log2-fold changes for these clusters between HD and HC (indicated by color, size and directionality of the triangles). Volcano plot of MAIT (d) and Treg (e) subpopulations by hierarchical gating. y-axis indicates Q value by Mann-Whitney U-test and Benjamini-

Hochberg false discovery rate correction, x-axis log2-fold change between HD and HC. Significantly altered subpopulations are depicted as box (median and interquartile range) and whiskers (min-max) with overlaid dot plots for MAIT and Treg in f) and g), respectively. For f and g, *P* values \leq 0.05 are shown, as measured by t test or Mann-Whitney-U test as appropriate.

- 525 Abbreviations: MAIT= mucosa-associated invariant T cells; Treg= regulatory T cells, HD=
- 526 hemodialysis, HC= healthy controls.

527 Tables

- **Table 1: Patients baseline characteristics.** Patients (n = 48) were grouped into four
- 529 categories (CKD = chronic kidney disease, HD = hemodialysis, KT = kidney transplantation,
- 530 HC = healthy controls). Data is shown as mean ± standard deviation or percentage (%) as
- 531 appropriate.

	НС	CKD G3-G4	HD	КТ
Patients (n)	10	12	11	15
Age (years)	12.1 ± 4.2	8.3 ± 2.3	13.6 ± 3.2	9.1 ± 2.9
Female	7 (70%)	5 (42%)	3 (27%)	6 (40%)
Diagnosis				
CAKUT	N/A	5 (42%)	5 (45%)	8 (53%)
Tubulointerstitial	N/A	2 (17%)	1 (9%)	3 (20%)
Glomerulopathy	N/A	4 (33%)	4 (36%)	3 (20%)
Post-AKI	N/A	1 (8%)	1 (9%)	1 (7%)
Healthy	10 (100%)	N/A	N/A	N/A
Caucasian	9 (90%)	12 (100%)	3 (27%)	11 (73%)
Weight (percentile)	61 ± 23	38 ± 21	8 ± 7	52 ± 28
BMI (percentile)	57 ± 21	35 ± 19	31 ± 19	59 ± 25
eGFR (ml/min/1.73 m²)	100.2 ± 29.3	29.6 ± 14.6	6.6 ± 1.1	78.6 ± 19.4
Urea (mg/dl)	30 ± 7	112 ± 67	147 ± 39	36 ± 14
Uric acid (mg/dl)	4.8 ± 1.3	7.6 ± 2.2	6.7 ± 1.2	5.4 ± 1.4
Phosphate (mmol/l)	1.3 ± 0.1	1.6 ± 0.3	2.0 ± 0.5	1.5 ± 0.3
Albumin (g/l)	47.7 ± 5.3	43.8 ± 13.0	38.0 ± 4.8	40.0 ± 3.4
CrP (mg/l)	2.6 ± 5.9	0.7 ± 1.1	3.6 ± 6.9	2.0 ± 1.8
PTH (pmol/l)	N/A	13.2. ± 8.5	38.5 ± 38.4	7.7 ± 3.8
Triglycerides (mg/dl)	N/A	166 ± 75	186 ± 54	112 ± 57
Antihypertensive treatment	0 (0%)	10 (83%)	10 (91%)	8 (53%)
Antihypertensive drugs (n)	0	1.8 ± 1.5	2.4 ± 1.9	0.8 ± 0.9
Arterial Hypertension	N/A	2 (17%)	6 (55%)	5 (33%)
(BP > 95 th Percentile)				

Abbreviations: CAKUT = congenital anomalies of the kidney and urinary tract; Post-AKI =

patients with chronic kidney disease after acute kidney injury; BP = blood pressure; N/A = not

534 applicable.

Gansevoort, R. T. et al. Chronic kidney disease and cardiovascular risk: epidemiology,

535 References

1

- 537 mechanisms, and prevention. Lancet 382, 339-352, doi:10.1016/S0140-6736(13)60595-4 538 (2013). 539 2 Claro, L. M. et al. The Impact of Uremic Toxicity Induced Inflammatory Response on the 540 Cardiovascular Burden in Chronic Kidney Disease. Toxins (Basel) 10, 541 doi:10.3390/toxins10100384 (2018). 542 3 Onal, E. M., Afsar, B., Covic, A., Vaziri, N. D. & Kanbay, M. Gut microbiota and inflammation in 543 chronic kidney disease and their roles in the development of cardiovascular disease. 544 Hypertens Res 42, 123-140, doi:10.1038/s41440-018-0144-z (2019). 545 4 Vanholder, R., Schepers, E., Pletinck, A., Nagler, E. V. & Glorieux, G. The uremic toxicity of 546 indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol 25, 1897-1907, 547 doi:10.1681/ASN.2013101062 (2014). 548 5 Vaziri, N. D. et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 83, 308-549 315, doi:10.1038/ki.2012.345 (2013). 550 6 Ramezani, A. et al. Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. 551 Am J Kidney Dis 67, 483-498, doi:10.1053/j.ajkd.2015.09.027 (2016). 552 7 Wang, X. et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in 553 humans and rodents. Gut 69, 2131-2142, doi:10.1136/gutjnl-2019-319766 (2020). 554 8 Holle, J. et al. Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease. Pediatr Nephrol, doi:10.1007/s00467-019-04331-6 (2019). 555 556 9 Harambat, J., van Stralen, K. J., Kim, J. J. & Tizard, E. J. Epidemiology of chronic kidney disease 557 in children. Pediatr Nephrol 27, 363-373, doi:10.1007/s00467-011-1939-1 (2012). 558 10 Rothhammer, V. & Quintana, F. J. The aryl hydrocarbon receptor: an environmental sensor 559 integrating immune responses in health and disease. Nat Rev Immunol 19, 184-197, 560 doi:10.1038/s41577-019-0125-8 (2019). 561 Quintelier, K. et al. Analyzing high-dimensional cytometry data using FlowSOM. Nat Protoc 11 562 16, 3775-3801, doi:10.1038/s41596-021-00550-0 (2021). 563 12 Abeles, R. D. et al. CD14, CD16 and HLA-DR reliably identifies human monocytes and their 564 subsets in the context of pathologically reduced HLA-DR expression by CD14(hi) /CD16(neg) 565 monocytes: Expansion of CD14(hi) /CD16(pos) and contraction of CD14(lo) /CD16(pos) 566 monocytes in acute liver failure. Cytometry A 81, 823-834, doi:10.1002/cyto.a.22104 (2012). 13 Wong, K. L. et al. Gene expression profiling reveals the defining features of the classical, 567 568 intermediate, and nonclassical human monocyte subsets. Blood 118, e16-31, 569 doi:10.1182/blood-2010-12-326355 (2011). 570 14 Duhen, T., Duhen, R., Lanzavecchia, A., Sallusto, F. & Campbell, D. J. Functionally distinct 571 subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 119, 572 4430-4440, doi:10.1182/blood-2011-11-392324 (2012). 573 15 Jankowski, J., Floege, J., Fliser, D., Bohm, M. & Marx, N. Cardiovascular Disease in Chronic 574 Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation 143, 1157-575 1172, doi:10.1161/CIRCULATIONAHA.120.050686 (2021). 576 16 Mitsnefes, M. M. Cardiovascular disease in children with chronic kidney disease. J Am Soc 577 Nephrol 23, 578-585, doi:10.1681/ASN.2011111115 (2012). 578 17 Schaefer, F. et al. Cardiovascular Phenotypes in Children with CKD: The 4C Study. Clin J Am 579 Soc Nephrol 12, 19-28, doi:10.2215/CJN.01090216 (2017). 580 18 Fasano, A. Zonulin and its regulation of intestinal barrier function: the biological door to 581 inflammation, autoimmunity, and cancer. Physiol Rev 91, 151-175, 582 doi:10.1152/physrev.00003.2008 (2011). 583 19 Yuan, J. H. et al. Impaired intestinal barrier function in type 2 diabetic patients measured by 584 serum LPS, Zonulin, and IFABP. J Diabetes Complications 35, 107766,
- 585 doi:10.1016/j.jdiacomp.2020.107766 (2021).

586	20	Tajik, N. et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of
587		arthritis. <i>Nat Commun</i> 11 , 1995, doi:10.1038/s41467-020-15831-7 (2020).
588	21	Schutt, C., Schilling, T., Grunwald, U., Schonfeld, W. & Kruger, C. Endotoxin-neutralizing
589		capacity of soluble CD14. <i>Res Immunol</i> 143 , 71-78, doi:10.1016/0923-2494(92)80082-v
590		(1992).
591	22	Poesen, R. <i>et al.</i> Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular
592		Disease, and Progression of Kidney Disease among Patients with CKD. Clin J Am Soc Nephrol
593		10 , 1525-1533, doi:10.2215/CJN.03100315 (2015).
594	23	Zanoni, I. & Granucci, F. Role of CD14 in host protection against infections and in metabolism
595		regulation. <i>Front Cell Infect Microbiol</i> 3 , 32, doi:10.3389/fcimb.2013.00032 (2013).
596	24	Stanislawski, M. A. et al. Soluble CD14 Levels in the Jackson Heart Study: Associations With
597		Cardiovascular Disease Risk and Genetic Variants. Arterioscler Thromb Vasc Biol 41, e369-
598		e378, doi:10.1161/ATVBAHA.121.316035 (2021).
599	25	Olson, N. C. <i>et al.</i> Soluble CD14, Ischemic Stroke, and Coronary Heart Disease Risk in a
600		Prospective Study: The REGARDS Cohort. J Am Heart Assoc 9 , e014241,
601		doi:10.1161/JAHA.119.014241 (2020).
602	26	Hiippala, K. <i>et al.</i> The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function
603	20	and Alleviating Inflammation. <i>Nutrients</i> 10 , doi:10.3390/nu10080988 (2018).
604	27	Geirnaert, A. <i>et al.</i> Butyrate-producing bacteria supplemented in vitro to Crohn's disease
605	27	patient microbiota increased butyrate production and enhanced intestinal epithelial barrier
606		integrity. <i>Sci Rep</i> 7 , 11450, doi:10.1038/s41598-017-11734-8 (2017).
607	28	Hobby, G. P. <i>et al.</i> Chronic kidney disease and the gut microbiome. <i>Am J Physiol Renal Physiol</i>
608	20	316 , F1211-F1217, doi:10.1152/ajprenal.00298.2018 (2019).
609	29	Gryp, T. <i>et al.</i> Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria
610	29	
	20	in Chronic Kidney Disease Patients. <i>Int J Mol Sci</i> 21 , doi:10.3390/ijms21061986 (2020).
611	30	Forslund, K. <i>et al.</i> Disentangling type 2 diabetes and metformin treatment signatures in the
612	24	human gut microbiota. <i>Nature</i> 528 , 262-266, doi:10.1038/nature15766 (2015).
613	31	Bouter, K. E., van Raalte, D. H., Groen, A. K. & Nieuwdorp, M. Role of the Gut Microbiome in
614		the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction. <i>Gastroenterology</i>
615		152 , 1671-1678, doi:10.1053/j.gastro.2016.12.048 (2017).
616	32	Chu, H., Williams, B. & Schnabl, B. Gut microbiota, fatty liver disease, and hepatocellular
617		carcinoma. <i>Liver Res</i> 2 , 43-51, doi:10.1016/j.livres.2017.11.005 (2018).
618	33	Roager, H. M. & Licht, T. R. Microbial tryptophan catabolites in health and disease. <i>Nat</i>
619		<i>Commun</i> 9 , 3294, doi:10.1038/s41467-018-05470-4 (2018).
620	34	Dodd, D. et al. A gut bacterial pathway metabolizes aromatic amino acids into nine
621		circulating metabolites. <i>Nature</i> 551 , 648-652, doi:10.1038/nature24661 (2017).
622	35	Vaziri, N. D., Yuan, J. & Norris, K. Role of urea in intestinal barrier dysfunction and disruption
623		of epithelial tight junction in chronic kidney disease. Am J Nephrol 37 , 1-6,
624		doi:10.1159/000345969 (2013).
625	36	Poesen, R. <i>et al.</i> Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl
626		sulfate in CKD. <i>Clin J Am Soc Nephrol</i> 8 , 1508-1514, doi:10.2215/CJN.00300113 (2013).
627	37	Dou, L. <i>et al</i> . Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney
628		disease. <i>Kidney Int</i> 93 , 986-999, doi:10.1016/j.kint.2017.11.010 (2018).
629	38	Schefold, J. C. et al. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum
630		levels of tryptophan catabolites in patients with chronic kidney disease: a possible link
631		between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant 24, 1901-
632		1908, doi:10.1093/ndt/gfn739 (2009).
633	39	Mair, R. D., Sirich, T. L. & Meyer, T. W. Uremic Toxin Clearance and Cardiovascular Toxicities.
634		<i>Toxins (Basel)</i> 10 , doi:10.3390/toxins10060226 (2018).
635	40	Debnath, S. et al. Tryptophan Metabolism in Patients With Chronic Kidney Disease Secondary
636		to Type 2 Diabetes: Relationship to Inflammatory Markers. Int J Tryptophan Res 10,
637		1178646917694600, doi:10.1177/1178646917694600 (2017).

638	41	Pawlak, K., Kowalewska, A., Mysliwiec, M. & Pawlak, D. Kynurenine and its metabolites
639		kynurenic acid and anthranilic acid are associated with soluble endothelial adhesion
640		molecules and oxidative status in patients with chronic kidney disease. Am J Med Sci 338 ,
641		293-300, doi:10.1097/MAJ.0b013e3181aa30e6 (2009).
642	42	Cussotto, S. <i>et al</i> . Tryptophan Metabolic Pathways Are Altered in Obesity and Are Associated
643		With Systemic Inflammation. <i>Front Immunol</i> 11 , 557, doi:10.3389/fimmu.2020.00557 (2020).
644	43	Duni, A. et al. The Association of Circulating CD14++CD16+ Monocytes, Natural Killer Cells
645		and Regulatory T Cells Subpopulations With Phenotypes of Cardiovascular Disease in a
646		Cohort of Peritoneal Dialysis Patients. Front Med (Lausanne) 8, 724316,
647		doi:10.3389/fmed.2021.724316 (2021).
648	44	Heine, G. H. <i>et al.</i> Monocyte subpopulations and cardiovascular risk in chronic kidney
649	••	disease. <i>Nat Rev Nephrol</i> 8 , 362-369, doi:10.1038/nrneph.2012.41 (2012).
650	45	Felizardo, R. J. F., Watanabe, I. K. M., Dardi, P., Rossoni, L. V. & Camara, N. O. S. The interplay
651	45	among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
652		<i>Pharmacol Res</i> 141 , 366-377, doi:10.1016/j.phrs.2019.01.019 (2019).
653	46	Bartolomaeus, H. <i>et al.</i> Short-Chain Fatty Acid Propionate Protects From Hypertensive
654	40	Cardiovascular Damage. Circulation 139 , 1407-1421,
655		doi:10.1161/CIRCULATIONAHA.118.036652 (2019).
656	47	Hsu, C. N., Lu, P. C., Hou, C. Y. & Tain, Y. L. Blood Pressure Abnormalities Associated with Gut
657	47	Microbiota-Derived Short Chain Fatty Acids in Children with Congenital Anomalies of the
658		Kidney and Urinary Tract. J Clin Med 8, doi:10.3390/jcm8081090 (2019).
659	48	Arpaia, N. <i>et al.</i> Metabolites produced by commensal bacteria promote peripheral regulatory
660	40	
	40	T-cell generation. <i>Nature</i> 504 , 451-455, doi:10.1038/nature12726 (2013).
661	49	Haghikia, A. <i>et al.</i> Propionate attenuates atherosclerosis by immune-dependent regulation of
662	F.0	intestinal cholesterol metabolism. <i>Eur Heart J</i> , doi:10.1093/eurheart J/ehab644 (2021).
663	50	Halim, L. <i>et al.</i> An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like
664		Tregs that Support a Tumorigenic Environment. <i>Cell Rep</i> 20 , 757-770,
665		doi:10.1016/j.celrep.2017.06.079 (2017).
666	51	Saigusa, R., Winkels, H. & Ley, K. T cell subsets and functions in atherosclerosis. <i>Nat Rev</i>
667		Cardiol 17, 387-401, doi:10.1038/s41569-020-0352-5 (2020).
668	52	Lowther, D. E. <i>et al.</i> PD-1 marks dysfunctional regulatory T cells in malignant gliomas. <i>JCI</i>
669		Insight 1 , doi:10.1172/jci.insight.85935 (2016).
670	53	Toubal, A. et al. Mucosal-associated invariant T cells promote inflammation and intestinal
671		dysbiosis leading to metabolic dysfunction during obesity. <i>Nat Commun</i> 11 , 3755,
672		doi:10.1038/s41467-020-17307-0 (2020).
673	54	Magalhaes, I. et al. Mucosal-associated invariant T cell alterations in obese and type 2
674		diabetic patients. <i>J Clin Invest</i> 125 , 1752-1762, doi:10.1172/JCI78941 (2015).
675	55	Touch, S. <i>et al.</i> Mucosal-associated invariant T (MAIT) cells are depleted and prone to
676		apoptosis in cardiometabolic disorders. FASEB J, fj201800052RR,
677		doi:10.1096/fj.201800052RR (2018).
678	56	Juno, J. A. <i>et al</i> . Mucosal-Associated Invariant T Cells Are Depleted and Exhibit Altered
679		Chemokine Receptor Expression and Elevated Granulocyte Macrophage-Colony Stimulating
680		Factor Production During End-Stage Renal Disease. Front Immunol 9 , 1076,
681		doi:10.3389/fimmu.2018.01076 (2018).
682	57	Swarte, J. C. et al. Characteristics and Dysbiosis of the Gut Microbiome in Renal Transplant
683		Recipients. <i>J Clin Med</i> 9 , doi:10.3390/jcm9020386 (2020).
684	58	Wu, H. et al. Gut Microbial Metabolites Induce Donor-Specific Tolerance of Kidney Allografts
685		through Induction of T Regulatory Cells by Short-Chain Fatty Acids. J Am Soc Nephrol,
686		doi:10.1681/ASN.2019080852 (2020).
687		
007		